Russia has eliminated the shortage of therapies for epilepsy and thyroid diseases

23 May 2022


Russia’s problem with the shortage of medicines for epilepsy and thyroid diseases has been solved. This was reported in the press service of the Ministry of Health of the Russian Federation.

“According to Roszdravnadzor, since the beginning of 2022, more than 1,6 million packages of drugs with INN Carbamazepine (a therapy for epilepsy) have been released into civil circulation under six trade names in various dosages and dosage forms. This is more than in the same period of 2021. Currently, there are more than 2,3 million packages of the drug with INN Carbamazepine in circulation in the Russian Federation,” the message says.

According to the department, in 2022, over 7,6 million packages of therapies for thyroid diseases with INN Levothyroxine sodium were released into civil circulation under four trade names (L-Thyroxine; L-Thyroxine Berlin-Chemie 50, 75, 100, 125, 150 mg; L-Thyroxine Renewal and Euthyrox).

According to the Ministry of Health, there are now more than 11,3 million packages of Levothyroxine sodium in circulation in the Russian Federation.

“The measures taken together with pharmaceutical manufacturers and distributors made it possible to normalize the situation that arose as a result of excessive demand,” the press service stated.




Read more


Read more

Media Center

Read more